Cannabis Law Report

SEPTEMBER 2, 2022

The clinical trial involving the use of Filament’s psilocybin received approval from Health Canada and was conducted as part of ATMA Journey Centre’s psychedelic-assisted therapist training program. was the first Canadian private company to engage in legally authorized psilocybin-assisted therapy. ATMA Journey Centers Inc.

Clinical Trials 52

Clinical Trials Therapy Programs Medicine 52

Project CBD

MARCH 2, 2020

In its ongoing search for alternatives to recreational cannabis, the National Institute on Drug Abuse ( NIDA ) has been funding research into much more dangerous and addictive drugs — ostensibly to help people ween off cannabis.

Clinical Trials 264

Clinical Trials Therapy Recreational Cannabis 264

Cannabis Law Report

NOVEMBER 17, 2022

The Finnish Medicines Agency (Fimea) has granted Clairvoyant Therapeutics, a Canadian drug company, permission to study the effects of psychedelic drug therapies for the treatment of alcohol addiction. Fimea’s approval marks the first time psychedelic drug trials will be carried out in Finland.

Therapy 52

Therapy Clinical Trials Treatment Medicine 52

Cannabis Law Report

JUNE 29, 2021

We look forward to his expertise as we expand our mental health analytical platform and enter clinical trials. ramps up to begin clinical trials by adding esteemed medical professional to its medical advisory board. Research in the area of mental health has been Dr. Nitin Desai’s passion. ” About Ehave, Inc.

Clinical Trials 105

Clinical Trials Research and Development Data Patients 105

Puff Puff Post

MARCH 10, 2020

INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases. About INM-755: INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Cannabis Law Report

JULY 13, 2022

Their position as therapeutic practitioners, as well as their work in conducting the kind of clinical trials necessary to advance regulatory outcomes for psychedelic medicines, make them ideal partners in alignment with Optimi’s strategic goals.”. VANCOUVER, British Columbia, July 13, 2022 (GLOBE NEWSWIRE) — Optimi Health Corp. (

Therapy 52

Therapy Clinical Trials Microdosing Research and Development 52

Cannabis Law Report

MAY 19, 2022

This is Numinus’ first psilocybin-assisted therapy treatment outside of ongoing clinical trials, and among the first to use of this regulatory mechanism through Health Canada’s Special Access Program (“SAP”), which was amended January 5 th , 2022 to include access to psychedelic compounds on a case-by-case basis.

Therapy 52

Therapy Treatment Clinical Trials Access 52

Cannabis Law Report

MARCH 18, 2022

Husch Blackwell has launched its Psychedelics and Emerging Therapie s team, an interdisciplinary, cross-office group of lawyers capable of addressing the challenges faced by innovators that seek to research, develop and commercialize novel therapies based on psychedelic drugs. By Steve Levine & Marshall Custer. March 18, 2022.

Therapy 52

Therapy Research and Development Clinical Trials Environment 52

Cannabis Law Report

FEBRUARY 24, 2022

Canada recently amended its Controlled Drugs and Substances Act (CDSA) to allow for psilocybin and MDMA therapy in limited circumstances. Each request is decided on a patient-by-patient basis and approval is usually only given to drugs with successful phase II or phase II clinical trials. Subsection 56(1) Exemption. Conclusion.

Therapy 52

Therapy Access Clinical Trials Treatment 52

Cannabis Law Report

DECEMBER 14, 2021

IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease. The primary endpoint of our Phase 1 clinical trial was to test and demonstrate safety and tolerability.

Clinical Trials 52

Clinical Trials Safety Data Patients 52

The Joint Blog

NOVEMBER 8, 2020

The study states: “[T]he impact of the intervention on quality of life in the cannabis group participants was evident, resulting in reports of well-being and more energy for activities of daily living. Pain attacks were also reduced.”. mg/mL of THC and 0.51 Results: There were no significant differences on baseline FIQ score between groups.

Clinical Trials 49

Clinical Trials Oil Therapy Marijuana 49

Cannabis Law Report

DECEMBER 2, 2021

(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.

Clinical Trials 52

Clinical Trials Data Patients THC 52

Cannabis Law Report

OCTOBER 4, 2021

Advanced Illness , Oregon Psilocybin Advisory Board , Oregon Psilocybin Services Act , Psilocybin , Psilocybin Therapy , Psychedelics , Right To Try. A multitude of recent clinical trials shows the clear promise of psilocybin for this population suffering from these debilitating conditions.

Therapy 52

Therapy Patients Law Clinical Trials 52

Cannabis Law Report

AUGUST 18, 2022

The firm’s deep expertise in pharmaceutical sciences, FDA regulatory compliance and pharmaceutical product liability litigation and risk management enables it to address complex legal hurdles faced by stakeholders seeking to research, develop, invest in and bring-to-market psychedelic therapies. BUFFALO, N.Y. , Aug. Tweet this.

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

Veriheal

JUNE 7, 2021

Always consult a physician before attempting alternative therapies. MDMA has also reportedly been used with over 1,000 individuals in clinical trials , with no adverse effects to report. . When consumed therapeutically, MDMA is administered through a process known as MDMA-Assisted Therapy.

Therapy 82

Therapy Treatment Conditions Clinical Trials 82

Cannabis Law Report

MARCH 7, 2023

Incannex Healthcare Limited, a pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic medicine therapies for unmet medical needs, announced that it has engaged Catalent (Catalent) to develop and manufacture a cGMP-grade psilocybin drug product for: (1) use in Incannex’s proprietary psilocybin-assisted psychotherapy (..)

Clinical Trials 52

Clinical Trials Therapy Pharmaceutical Medicine 52

Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood. No approved TNF inhibitor has ever been dosed orally.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Veriheal

JUNE 30, 2023

A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Cannabis Law Report

MAY 19, 2022

Before January, people could only access psychedelic-assisted psychotherapy through clinical trials or medical exemptions. In April, a clinic called Roots To Thrive, in Nanaimo, B.C., became the first health centre in Canada to offer a legal psilocybin group therapy program, in which Hartle took part.

Therapy 52

Therapy Patients Treatment Clinical Trials 52

Puff Puff Post

MARCH 10, 2020

INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases. About INM-755: INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

The Joint Blog

APRIL 16, 2020

According to a new study cannabis may be a useful adjunct therapy for those undergoing radiation therapy, although more research is needed to confirm this. The study is published in the Journal of Medical Imaging and Radiation Sciences and titled Cannabis and Radiation Therapy: A Scoping Review of Human Clinical Trials.

Therapy 63

Therapy Clinical Trials Patients Cannabinoids 63

Veriheal

AUGUST 28, 2023

New therapy exploration suggest potential in using psilocybin for OCD symptoms. And it further reinforces the need to carry out clinical trials to determine the safety and efficiency of using psilocybin to treat OCD. Preliminary findings have suggested that mental health patients could go through psilocybin-assisted therapy.

Treatment 63

Treatment Clinical Trials Therapy Research and Development 63

Cannabis Law Report

MAY 6, 2021

EMDMA-001 has been modelled on a major Phase III clinical trial developed by the Multidisciplinary Association for Psychedelic Studies (MAPS).… … Read More.

Clinical Trials 59

Clinical Trials Therapy Programs Medicine 59

CannaMD

AUGUST 26, 2020

A new review published by scientific journal, Pharmacology Biochemistry and Behavior , has found that marijuana cannabinoid, CBD, is a “promising” therapy for treating cocaine dependence. Find out more about the studies scientists reviewed – and why they think cannabis could help cocaine addiction – below! mice/rats).

Therapy 98

Therapy CBD Research and Development Treatment 98

Cannabis Law Report

AUGUST 10, 2022

According to CAMH’s lead investigator, clinical trials suggest that psilocybin, combined with psychotherapy, can produce “ sustained antidepressant effects” in individuals living with severe depression.

Clinical Trials 52

Clinical Trials Research and Development Therapy Microdosing 52

Cannabis Law Report

JULY 15, 2021

Halucenex to progress phase II clinical trial to test the efficacy of psilocybin when used to treat Post Traumatic Stress Disorder (PTSD). ? Halucenex’s operation progress continues – USP 61 test protocols complete providing additional validation of psilocybin compounds ahead of Clinical Trial Application. ? 02395733.

Clinical Trials 96

Clinical Trials Therapy Treatment Access 96

Cannabis Law Report

DECEMBER 5, 2021

Revenue share payments will be based on North America sales of MDMA for use in MDMA-assisted therapy, will terminate after 8 years, and include a reciprocity payment structure that reduces payments once certain financial milestones are met. The safety and efficacy of MDMA-assisted therapy is currently under investigation.

Therapy 52

Therapy Access Research and Development Clinical Trials 52

Veriheal

JULY 24, 2023

Looking For Depression Relief — Jaden Smith Found Mushrooms Jaden Smith’s speech focused on the growing field of psychedelic therapy. Want to learn more about the Smith family’s embrace of psychedelic therapy? The post Jaden Smith Talks Depression, Psilocybin & Family “Trips” appeared first on Cannabis Central.

Therapy 97

Therapy Clinical Trials Treatment Cannabis 97

Cannabis Law Report

AUGUST 7, 2021

We are currently focused on developing MDMA-assisted therapy as a Breakthrough Therapy for PTSD, with plans to submit for FDA approval in 2023. The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times. Key Responsibilities.

Clinical Trials 105

Clinical Trials Research and Development Compliance Compliance 105

Veriheal

MAY 25, 2023

What was once used as an ideal anesthetic for monkeys could soon be competing with cannabis as a medical aid. The substance’s versatility cannot be ignored, but how exactly does it fare against cannabis? Ketamine Clinics Are an Evolutionary Addition to U.S. In Manhattan alone, 12 clinics have already opened their doors.

Medicine 98

Medicine Blood Pressure Therapy Clinical Trials 98

Cannabis Law Report

SEPTEMBER 10, 2021

Nick Milne PhD, Co-founder and CSO of Octarine said: “Our core ambition at Octarine is to advance psychedelic therapy across Europe and the world in a way that is consistent with sustainability principles while ensuring patient accessibility.

Research and Development 104

Research and Development Clinical Trials Therapy Environment 104

Canna Care Docs

OCTOBER 3, 2023

Natural plant therapy , and cannabis specifically, has been studied for its effectiveness in alleviating and treating many of these physiological and emotional symptoms that come into play with a terminal illness. Nausea and Vomiting Control One of the most common physical symptoms of terminally ill patients is nausea and vomiting.

Chronic Pain 105

Chronic Pain Clinical Trials Patients Cannabinoids 105

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. This is the largest trial ever conducted in psilocybin therapy, and it was done amid the lockdowns and challenges of the COVID pandemic. million, or $0.79

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

APRIL 21, 2022

The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals. in each of the four validation trials with an acceptable yield, which is a noteworthy accomplishment. MEDIA CONTACT .

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

Veriheal

MARCH 20, 2023

Alternative medicine is becoming more widely acknowledged and practiced than ever before, opening the door for therapies like psychedelics to enter the world of mainstream healthcare. Psilocybin therapy is both studied and used by highly legitimate medical establishments. Ned Lamont signed a bill (HB 5506) to fund psychedelic therapy.

Clinical Trials 98

Clinical Trials Therapy Decriminalization Treatment 98

Cannabis Law Report

MAY 31, 2022

Two approaches apply to commercial operations—the traditional medical path and the emerging non-medical state-regulated path, while the other two paths are better seen as non-commercial—underground therapy and religious use. 2022 Active FDA Clinical Trials and State-Regulated Systems. Active FDA Regulated Clinical Trials*.

Clinical Trials 52

Clinical Trials Legalization Therapy Decriminalization 52

Cannabis Law Report

JULY 28, 2021

The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health. The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study.

Clinical Trials 81

Clinical Trials Research and Development Treatment Therapy 81